News

@pharma_indian
indianpharmapost. com > rd > wacker-launches-contract-research-services-to-accelerate-next-gen-rna-dna-therapies-20324

WACKER launches contract research services to accelerate next-gen RNA & DNA therapies

1+ day, 15+ hour ago  (95+ words) The new CRS offering is delivered from WACKER's Biotechnology Center in Munich provides Contract Research Services (CRS) for R&D-grade p DNA, RNA and LNPs for preclinical studies. Source: WACKER Maxivision appoints Surya K as Group Head " Medical Affairs and…...

Symbols: nikkei,d05.S0,u11.S0,z74.S0,i11.S0,585.S0
Google News
indianpharmapost. com > news > merck-doses-first-patient-in-phase-3-trial-of-novel-antibody-drug-conjugate-for-metastatic-colorectal-cancer-20320

Merck doses first patient in Phase 3 trial of novel antibody-drug conjugate for metastatic colorectal cancer

1+ day, 21+ hour ago  (86+ words) The trial will assess Precem-Tc T, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments Maxivision appoints Surya K as Group Head " Medical Affairs and Quality Shreevar Kheruka…...

Symbols: nasdaq:oncy,nasdaq:adag,nasdaq:incy
@pharma_indian
indianpharmapost. com > clinical-trials > eli-lillys-retatrutide-delivers-up-to-30-weight-loss-in-phase-3-trial-20321

Eli lilly's retatrutide delivers up to 30% weight loss in phase 3 trial

1+ day, 20+ hour ago  (66+ words) Clears major obesity endpoints at 80 weeks Maxivision appoints Surya K as Group Head " Medical Affairs and Quality Shreevar Kheruka appointed Managing Director at Borosil Limited Fortis Healthcare FY26 revenue crosses Rs. 9, 100 crore Merck doses first patient in Phase 3 trial of novel…...

Symbols: nyse:lly
Google News
indianpharmapost. com > news > fortis-healthcare-fy26-revenue-crosses-rs-9100-crore-20319

Fortis Healthcare FY26 revenue crosses Rs. 9, 100 crore

1+ day, 23+ hour ago  (435+ words) Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum Fortis Healthcare reported a strong financial performance for the fourth quarter and full year ended March 31, 2026, led by sustained growth in its hospital business, improving operating margins,…...

Symbols: nyse:fts
@pharma_indian
indianpharmapost. com > news > jubilant-pharmova-posts-fy26-revenue-of-rs-8280-crore-up-14-20315

Jubilant Pharmova posts FY26 revenue of Rs. 8, 280 crore, up 14%

2+ day, 7+ hour ago  (414+ words) Q4 FY26 revenue climbs 19% to Rs. 2, 290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum Jubilant Pharmova Limited reported strong operational performance for FY26, with consolidated revenue rising 14% year-on-year to Rs. 8, 280 crore. The growth was supported by robust growth across…...

Symbols: nyse:jmia
@pharma_indian
indianpharmapost. com > drug-approval > venus-remedies-secures-global-approval-for-plerixafor-in-saudi-arabia-20311

Venus Remedies secures global approval for Plerixafor in Saudi Arabia

2+ day, 11+ hour ago  (225+ words) SFDA nod marks company's strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region Venus Remedies Limited has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA)…...

Symbols: nasdaq:sngx
@pharma_indian
indianpharmapost. com > drug-approval > venus-remedies-secures-first-ever-global-approval-for-plerixafor-in-saudi-arabia-20311

Venus Remedies secures first-ever global approval for Plerixafor in Saudi Arabia

2+ day, 15+ hour ago  (225+ words) SFDA nod marks company's strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region. Venus Remedies Limited has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA)…...

Symbols: nasdaq:sngx
Google News
indianpharmapost. com > opinion > multimodal-ai-emerges-as-next-leap-in-predictive-healthcare-20310

Multimodal AI emerges as next leap in predictive healthcare: Ashwattha Sahasrabuddhe, Principal Architect and Technology & Practice Head " Healthcare Business, Tata Elxsi

2+ day, 22+ hour ago  (459+ words) Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond Converging Data Silos into Clinical Intelligence In India, the Ayushman Bharat Digital Mission (ABDM) and its Ayushman Bharat Health Account (ABHA) framework are beginning…...

Symbols: nyse:rmd,asx:rmd
INDIANCHEMICALNEWS
indianpharmapost. com > news > lite > hansa-biopharma-licenses-idefirix-to-serb-pharmaceuticals-in-115-million-deal-20293

Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in "115 million deal

3+ day, 5+ hour ago  (277+ words) SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization Jeremie Urbain, Chairman of SERB, said "SERB is committed to expanding access to transplantation for highly sensitized patients who currently have…...

Symbols: btc-usd
@pharma_indian
indianpharmapost. com > people > eli-lilly-appoints-chandan-s-as-senior-director-for-data-science-and-ai-engineering-20304

Eli Lilly appoints Chandan S. as Senior Director for Data Science and AI Engineering

2+ day, 23+ hour ago  (208+ words) AI and analytics leader brings extensive expertise in machine learning, Gen AI, and life sciences decision intelligence to Lilly's data science operations Chandan S. has joined Eli Lilly and Company as Senior Director " Data Science and AI Engineering. He brings significant…...

Symbols: nyse:lly